secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001213900-23-081324
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Blue Water Biotech appoints Dr. Neil Campbell as CEO and Bruce Harmon as CFO effective October 4, 2023
--------------------------------------------------------------------------------

- Dr. Neil Campbell appointed President & CEO and board member; replaces prior plan for James Sapirstein as Interim Executive Chairman.
- Bruce Harmon appointed CFO, replacing Jon Garfield who resigned; Garfield receives $72,500 severance.
- Campbell receives $75,000 signing bonus, $475,000 base salary, option to purchase 3% of outstanding shares.
- Harmon receives $325,000 base salary, option to purchase 1% of outstanding shares.
- James Sapirstein appointed non-executive Chairman of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383-8k_bluewater.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-081324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer